US 12024570
Anti-CTLA-4 antibodies and uses thereof
granted A61KA61K2039/507A61K2039/545
Quick answer
US patent 12024570 (Anti-CTLA-4 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/507, A61K2039/545, A61K2300/00, A61K39/395